Le Lézard
Classified in: Health
Subjects: CCA, PET, ANW

Petco Health and Wellness Company, Inc. to Host Third Quarter 2023 Earnings Conference Call on November 29, 2023


SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- On November 29, 2023, at approximately 7:00 a.m. Eastern, Petco Health and Wellness Company, Inc. (Nasdaq: WOOF), a complete partner in pet health and wellness, will release its third quarter 2023 earnings results.

Additionally, Petco executives will host a conference call at approximately 8:00 a.m. Eastern to review the company's financial and operating performance.

The call will be webcast live and the earnings release, earnings presentation, and infographic will be available on the company's Investor Relations page at ir.petco.com. A replay of the webcast will also be available online approximately two hours after the conference call, until approximately 5:00 p.m. Eastern on December 13, 2023, through the company's Investor Relations page.

About Petco, The Health + Wellness Co.

Founded in 1965, Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. We've consistently set new standards in pet care while delivering comprehensive pet wellness products, services and solutions, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 pet care centers across the U.S., Mexico and Puerto Rico, which offer merchandise, companion animals, grooming, training and a growing network of on-site veterinary hospitals and mobile veterinary clinics. Our complete pet health and wellness ecosystem is accessible through our pet care centers and digitally at petco.com and on the Petco app. In tandem with Petco Love, a  life-changing organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we've helped find homes for nearly 7 million animals. 

SOURCE Petco - Investor Relations


These press releases may also interest you

at 08:15
Nuvation Bio Inc. , a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its...

at 08:05
Takeda (TSE:4502/NYSE:TAK) and Pfizer today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking...

at 08:05
Summit Therapeutics Inc. ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A...

at 08:05
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or...

at 08:05
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature...

at 08:05
Pfizer Inc. today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse...



News published on and distributed by: